New Zealand - English - Medsafe (Medicines Safety Authority)

w m bamford & co ltd - hematoporphyrin 0.2mg; procaine hydrochloride 50mg - capsule - active: hematoporphyrin 0.2mg procaine hydrochloride 50mg excipient: erythrosine gelatin lactose monohydrate magnesium carbonate monobasic sodium phosphate dihydrate potassium chloride purified talc sodium laurilsulfate

Australia - English - Department of Health (Therapeutic Goods Administration)

catalent australia pty ltd - ascorbic acid,calcium pantothenate,dl-alpha-tocopheryl acetate,eleutherococcus senticosus,hematoporphyrin dihydrochloride,lecithin,linseed oil,magnesium diglutamate tetrahydrate,nicotinamide,potassium chloride,pyridoxine hydrochloride,retinol palmitate,riboflavine,sunflower oil,thiamine nitrate,troxerutin,wheatgerm oil -

Canada - English - Health Canada

concordia laboratories inc - porfimer sodium - powder for solution - 75mg - porfimer sodium 75mg - antineoplastic agents

Canada - English - Health Canada

concordia laboratories inc - porfimer sodium - powder for solution - 15mg - porfimer sodium 15mg - antineoplastic agents

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - edetate calcium disodium (unii: 25ih6r4sgf) (edetic acid - unii:9g34hu7rv0) - edetate calcium disodium injection is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults. chelation therapy should not replace effective measures to eliminate or reduce further exposure to lead. edetate calcium disodium injection should not be given during periods of anuria, nor to patients with active renal disease or hepatitis.

United States - English - NLM (National Library of Medicine)

casper pharma llc - edetate calcium disodium (unii: 25ih6r4sgf) (edetic acid - unii:9g34hu7rv0) - edetate calcium disodium injection is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults. chelation therapy should not replace effective measures to eliminate or reduce further exposure to lead. edetate calcium disodium injection should not be given during periods of anuria, nor to patients with active renal disease or hepatitis.

Namibia - English - Namibia Medicines Regulatory Council

adcock ingram ltd - haematoporphyrin 0,75 mg; ; cyanocobalamin 0,75 mg; caffeine anhydrous18,75 mg; ; extract yeast soluble (irradiated) 37,5 mg - syrup - each 5ml contains: ; haematoporphyrin 0,75 mg; ; cyanocobalamin 0,75 mg; ; caffeine anhydrous18,75 mg; ; extract yeast soluble (

New Zealand - English - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - calcium carbonate 42.4 mg/ml; edetic acid 123.7 mg/ml; sodium hydroxide 33.9 mg/ml - solution for injection - 1g/5ml - active: calcium carbonate 42.4 mg/ml edetic acid 123.7 mg/ml sodium hydroxide 33.9 mg/ml excipient: water for injection

United States - English - NLM (National Library of Medicine)

bausch health us, llc - edetate calcium disodium (unii: 25ih6r4sgf) (edetic acid - unii:9g34hu7rv0) - edetate calcium disodium 200 mg in 1 ml - edetate calcium disodium is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults. chelation therapy should not replace effective measures to eliminate or reduce further exposure to lead. edetate calcium disodium should not be given during periods of anuria, nor to patients with active renal disease or hepatitis.

European Union - English - EMA (European Medicines Agency)

clinuvel europe limited - afamelanotide - protoporphyria, erythropoietic - emollients and protectives - prevention of phototoxicity in adult patients with erythropoietic protoporphyria (epp).